# Johnson & Johnson Reports 5.8% Revenue Growth as U.S. Sales Rise 9.1% By John Kim Canonical URL: https://www.tokenpost.com/news/business/31043 Published: 2026-10-13T11:08:22.000Z Updated: 2026-10-13T11:08:22.000Z Section: Business > Third-quarter revenue reached $25.4 billion, while non-GAAP earnings per share came to $2.59 and the 2026 sales outlook increased to $101.2 billion. Johnson & Johnson’s U.S. sales rose 9.1% year over year in the third quarter as growth in its innovative-medicine business helped offset weaker Stelara sales. Revenue reached $25.4 billion, up 5.8% from a year earlier and in line with expectations. Non-GAAP earnings per share came to $2.59, exceeding expectations by 6 cents. The company also raised its 2026 reported-sales outlook to $101.2 billion at the midpoint. The updated forecast represents 7.4% growth. Johnson & Johnson maintained its quarterly dividend at $1.34 per share. The dividend amount was unchanged from the previous distribution. The results build on [Johnson & Johnson’s latest sales and earnings update](), which also covered the company’s higher 2026 sales outlook. ## Links in this article - [Johnson & Johnson’s latest sales and earnings update](https://www.tokenpost.com/news/business/31007)